In this week’s View, Dr. Eagle explores the associations of apixaban dose with safety and effectiveness outcomes in patients with atrial fibrillation and severe chronic kidney disease. He then discusses a study that looks at stroke risk in women with atrial fibrillation. Finally, Dr. Eagle examines the DCM Precision Medicine Study of rare variant genetics and dilated cardiomyopathy severity.   Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle explores the association of coronary artery calcium detected by routine ungated CT imaging with cardiovascular outcomes. He then discusses the outcomes of repeat transcatheter aortic valve replacement with balloon-expandable valves. Finally, Dr. Eagle reviews a mechanistic study on atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events.   Subscribe to Eagle’s Eye View

In this special edition of the View, Dr. Eagle summarizes the top trials that were presented at the ESC Congress in Amsterdam from Friday, Aug. 25 through Monday, Aug. 28.    Dr. Eagle discusses STEP-HFpEFF, evaluating the targeting of therapy in patients with the obesity phenotype and heart failure with preserved ejection fraction. He then looks at STOP-DAPT3 exploring the benefit of the prasugrel monotherapy without aspirin as compared with the 1-month dual therapy with aspirin and prasugrel. ESC also presented ONCO DVT, looking at the optimal duration of anticoagulation therapy, and at ILLUMEN-IV investigating the superiority of an Optical Coherence Tomography (OCT)-guided stent implantation strategy.   Dr. Eagle also looks at three trials with negative results that still offer important insights, including ARREST, comparing survival in hospital discharge between two standards of care after arrival at the hospital, ECLS-Shock investigates extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock and COP-AF, exploring colchicine for the prevention of perioperative atrial fibrillation in patients undergoing thoracic surgery.   Subscribe to Eagle’s Eye View

In this special edition of the View, Kim A. Eagle, MD, MACC, talks with Dharam J. Kumbhani, MD, SM, FACC, Philippe Gabriel Steg, MD, FACC, and Payal Kohli, MD, FACC, about three of the major trials presented Monday, Aug. 28 during ESC Congress 2023.   The trials include ARAMIS (0:39), investigating potential treatments for acute myocarditis, RIGHT (3:22), exploring STEMI patients treated with primary PCI, evaluating the prolongation of anticoagulation after the procedure and ONCO-DVT (4:51), looking at the optimal duration of anticoagulation therapy (3 months vs. 12 months) with direct oral anticoagulant (edoxaban) for isolated distal deep vein thrombosis.  Subscribe to Eagle’s Eye View

In this special edition of the View, Kim A. Eagle, MD, MACC, talks with Dharam J. Kumbhani MD, SM, FACC, Philippe Gabriel Steg, MD, FACC, and Payal Kohli, MD, FACC, about four of the major trials that were presented on Day 3 of the ESC Congress in Amsterdam on Sunday, Aug. 27.   The trials include ATTRIBUTE-CM (00:39), investigating the efficacy and safety of acoramidis in subjects with symptomatic transthyretin amyloid cardiomyopathy (ATTR-CM). MULISTARS (03:15), investigating patients presenting with ST segment elevation myocardial infarction (STEMI) and multi-vessel disease (MVD), comparing the safety and efficacy of immediate complete revascularization of all significant coronary lesions vs. culprit vessel only revascularization and staged percutaneous coronary intervention (PCI) of all significant coronary. ILLUMEN-IV (06:28) to demonstrate the superiority of an Optical Coherence Tomography (OCT)-guided stent implantation strategy as compared to an angiography-guided stent implantation strategy in achieving larger post-PCI lumen dimensions and improving clinical cardiovascular outcomes in patients with high-risk clinical characteristics and/or with high-risk angiographic lesions and the ARREST (10:02) Trial, comparing survival to hospital discharge between two standards of care after arrival at the hospital: emergency department-based standard ACLS resuscitation vs. early ECMO-facilitated resuscitation.  Subscribe to Eagle’s Eye View

In this special edition of the View, Kim A. Eagle, MD, MACC, talks with Philippe Gabriel Steg, MD, FACC, and Payal Kohli, MD, FACC, about four of the major trials that were presented on Day 2 of the ESC Congress in Amsterdam on Saturday, Aug. 26. The trials include ECLS-SHOCK (0:44) that investigates extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock, CLEAR-Outcomes (03:34), looking at bempedoic acid and cardiovascular outcomes in statin-intolerant patients, STOPDAPT 3 (06:33) exploring the benefit of the prasugrel monotherapy without aspirin as compared with the 1-month dual therapy with aspirin and prasugrel in terms of reducing bleeding events after PCI using cobalt-chromium everolimus-eluting stents in patients with high bleeding risk or acute coronary syndrome patients, and FIRE (09:47) studying functional vs. culprit-only revascularization in elderly patients with myocardial infarction and multivessel disease.

In this special edition of the View, Dr. Eagle talks with Dharam J. Kumbhani MD, SM, FFACC, MACC, Philippe Gabriel Steg MD, and Payal Kohli MD about four of the major trials that were presented on Day 1 of the ESC Congress in Amsterdam on Friday, August 25. The trials include COP-AF (0:40), exploring colchicine for the prevention of perioperative atrial fibrillation in patients undergoing thoracic surgery, BIOFLOW DAPT (3:18), a prospective, randomized, multicenter study to assess the safety of the Orsiro Mission stent compared to the Resolute Onyx stent in subjects at high risk for bleeding in combination with 1-month dual antiplatelet therapy, STEP HFpEF (7:18), evaluating the targeting of therapy in patients with the obesity phenotype with patients with heart failure with preserved ejection fraction, and SHARE (10:26), looking at antiplatelet therapy after PCI.

In this week’s View, Dr. Eagle explores the impact of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors on the recurrence of atrial fibrillation after catheter ablation in patients with type-2 diabetes, then discusses the differences and similarities between the ACC/AHA and ESC/EACTS guidelines for the management of valvular heart diseases. Finally, Dr. Eagle looks at data from the VICTORIA Trial and asks whether age or sex affect the outcome of patients with heart failure with reduced ejection fraction.  Subscribe to Eagle’s Eye View

In this special edition of the View, Dr. Eagle discusses some of the major trials and guidelines that are at the center of this year’s ESC Congress 2023, taking place in Amsterdam from Friday, August 25 to Monday, August 28.  ACC.org will be covering all the high points of this year’s Congress, including late-breaking trials with a special focus on interventional cardiology, as well as major papers on atrial fibrillation, heart failure, shock, and much more.   Among the trials that will be under discussion are COP-AF, HEART–FID, ECLS Shock, STOP-DAPT3, ILUMIEN 4, OCTAVUS, ARREST, FRAIL-AF, and OPT-BIRISK. ACC.org will also explore a number of important new ESC Guidelines and updates on topics ranging from endocarditis, CVD and diabete, and cardiomyopathy to acute coronary syndrome, as well updates on the 2023 Heart Failure Guidelines.    For more information, check out ACC.org’s trial summaries, key points documents on the guidelines, press releases and visual abstracts, as well as regular updates on social media. ACC.org will also be releasing video summaries of each day’s highlights, as well as audio versions of those highlights for each day of the conference, releasing here on Eagle’s Eye View.  Amsterdam is a lovely city, but if you cannot attend in person, you can have access to all the vital news and clinical data from ESC Congress 2023 here on Eagle’s Eye View and on acc.org.  Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle explores what cardiologists should know about migraine and cardiovascular disease. Dr. Eagle then looks at microvascular resistance reserve and its diagnostic and prognostic performance in the ILIAS registry.  Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle explores the use of high-sensitivity cardiac troponin for risk assessment in patients with chronic coronary artery disease. He then explores the potential of using low-dose colchicine for secondary prevention of coronary artery disease. Finally, Dr. Eagle looks at the use of beta-blockers and heart failure outcomes in patients with mildly reduced or preserved ejection fraction. Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle explores a study looking at the long-term safety and efficacy of the subcutaneous implantable cardioverter-defibrillator system. He then explores combination lipid-lowering therapy in patients undergoing PCI versus statin therapy alone. Finally, Dr. Eagle looks at an important article on raced-based differences in the management of ST segment elevation myocardial infarction.  Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle explores the association of successful percutaneous revascularization of chronic total occlusions with quality of life. He then discusses the feasibility and safety of flecainide use among patients with varying degrees of coronary disease. Finally, Dr. Eagle looks at an incredibly important meta-analysis on the racial differences in quality of life among patients with heart failure who are treated with sodium-glucose cotransporter 2 inhibitors.  Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle explores thirty-day outcomes of tricuspid edge-to-edge repair in clinical practice. He then discusses a study of the ISCHEMIA Trial, specifically the outcomes of patients who had complete revascularization versus those who did not. Finally, Dr. Eagle looks at decompression illness in divers with and without patent foramen ovale.  Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle explores a JACC State-of-the-Art Review of consumer wearable health and fitness technology and its role in cardiovascular medicine. He then discusses the 2023 update of the European Atherosclerosis Society’s consensus statement on homozygous familial hypercholesterolemia that offers new treatments and clinical guidance. Finally, Dr. Eagle looks at a recent post-hoc analysis of the SPRINT Trial on the effect of frailty on the efficacy and safety of intensive blood pressure control.  Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle explores a study on the effect of low-dose aspirin vs. placebo on the development of anemia. He then discusses the PARAGLIDE-HF study on the use of ARNI agents in patients with mildly reduced or preserved ejection fraction and worsening heart failure. Finally, Dr. Eagle looks at the very important study on the value of bempedoic acid in primary prevention for patients who are statin-intolerant.  Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle explores the long-term mortality of patients with Ebstein Anomaly. He then discusses a study that looks at the modifiability of cardiovascular risk associated with chronic kidney disease in patients with type 2 diabetes treated with finerenone. Finally, Dr. Eagle looks at the effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations.   Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle explores familial associations and prevalence of cause-specific mortality for thoracic aortic disease and bicuspid aortic valve disease. He then discusses a patient-level network meta-analyses from COMBINE that compares the use of direct-acting oral anticoagulants versus warfarin across the spectrum of kidney function. Finally, Dr. Eagle looks at biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients, as the field of cardio-oncology continues to evolve and grow.  Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle discusses one of the most important topics he has covered on the podcast this year: the proper measurement of blood pressure in the office and at home. He then explores the use of beta blockers in patients with stable ischemic heart disease. Finally, Dr. Eagle looks at PCI or CABG for left main coronary artery disease, as investigated in the SWEDEHEART registry.  Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle looks at SCORE2-Diabetes, a 10-year CV risk estimator for patients with type 2 diabetes. He then discusses the value of sex-specific stress perfusion cardiac MRI in suspected ischemic heart disease. Finally, Dr. Eagle explores a paper on managing patients with moderate aortic valve stenosis.  Subscribe to Eagle’s Eye View